Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05380128
Other study ID # BeijingTH-20220509
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2017
Est. completion date May 9, 2022

Study information

Verified date May 2022
Source Beijing Tongren Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Vitamin D receptor gene (VDR) polymorphisms are the candidate genetic variants for susceptibility to autoimmune diseases. In the present study, the investigators aimed to assess the association between VDR polymorphisms and myasthenia gravis (MG) susceptibility and disease features in Chinese Han population.The patients with MG and healthy controls were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms using the improved multiple ligase detection reaction. Information on age at onset, acetylcholine receptor antibody (AChR-Ab) and muscle-specific kinase antibody (MuSK-Ab) status, thymus status, involved muscles at onset and Osserman type at the maximum worsening during 2 years follow-up were obtained and used as the grouping basis of sub-classifications. Intergroup comparisons of allele and genotype frequencies, haplotype distributions were performed between MG group and the control group, and between each pair of MG subgroups.


Recruitment information / eligibility

Status Completed
Enrollment 297
Est. completion date May 9, 2022
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Clinical diagnosis of myasthenia gravis. - Han Chinese population. - Must be able to complete a 2-year follow-up visit. Exclusion Criteria: - Clinical data collection can not be completed. - Poor compliance.

Study Design


Intervention

Genetic:
Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).

Locations

Country Name City State
China Beijing Tongren Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tongren Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association between VDR gene polymorphism and MG susceptibility Codominant, dominant and recessive genetic models and haplotype analysis were applied to compare the difference between MG and control groups. up to 2 years
Secondary Association of VDR gene polymorphism with MG subgroups To study the precise effect of single nucleotide polymorphisms (SNPs) in the different population, the MG patients were divided into subgroups according to essential clinical variables, including onset age (=50 or >50 years), thymus status (thymoma or non-thymoma, by pathology), AChR / MuSK Abs (positive or negative), onset involvement (ocular or generalized) and Osserman type at the maximum worsening (type I or IIa-IIb or III-V). The investigators analyzed the distribution of genes in each group. up to 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04735913 - Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults Early Phase 1
Recruiting NCT05503095 - PCSK9 Polymorphism and Risk of Cardiac Rupture
Recruiting NCT04960774 - Risk Factors for Severe Periodontitis in 30 to 40 Year Olds: a Retrospective Study